ALX Oncology Holdings, Inc. (ALXO)
2.00
+0.01
(+0.50%)
USD |
NASDAQ |
Aug 25, 16:00
2.00
0.00 (0.00%)
After-Hours: 19:32
ALX Oncology Holdings Enterprise Value : 147.86M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 147.86M |
| August 21, 2026 | 154.77M |
| August 20, 2026 | 147.86M |
| August 19, 2026 | 157.53M |
| August 18, 2026 | 160.30M |
| August 17, 2026 | 145.09M |
| August 14, 2026 | 143.71M |
| August 13, 2026 | 140.95M |
| August 12, 2026 | 150.62M |
| August 11, 2026 | 139.57M |
| August 10, 2026 | 157.53M |
| August 07, 2026 | 163.06M |
| August 06, 2026 | 164.45M |
| August 05, 2026 | 138.18M |
| August 04, 2026 | 145.09M |
| August 03, 2026 | 139.57M |
| July 31, 2026 | 140.95M |
| July 30, 2026 | 142.33M |
| July 29, 2026 | 141.64M |
| July 28, 2026 | 147.86M |
| July 27, 2026 | 152.01M |
| July 24, 2026 | 153.39M |
| July 23, 2026 | 152.01M |
| July 22, 2026 | 152.01M |
| July 21, 2026 | 156.15M |
| Date | Value |
|---|---|
| July 20, 2026 | 138.18M |
| July 17, 2026 | 163.06M |
| July 16, 2026 | 158.92M |
| July 15, 2026 | 153.39M |
| July 14, 2026 | 149.24M |
| July 13, 2026 | 145.09M |
| July 10, 2026 | 166.52M |
| July 09, 2026 | 157.53M |
| July 08, 2026 | 194.85M |
| July 07, 2026 | 199.00M |
| July 06, 2026 | 175.50M |
| July 02, 2026 | 158.92M |
| July 01, 2026 | 157.53M |
| June 30, 2026 | 158.92M |
| June 29, 2026 | 168.71M |
| June 26, 2026 | 147.19M |
| June 25, 2026 | 113.55M |
| June 24, 2026 | 113.55M |
| June 23, 2026 | 109.52M |
| June 22, 2026 | 92.03M |
| June 18, 2026 | 78.57M |
| June 17, 2026 | 67.81M |
| June 16, 2026 | 58.39M |
| June 15, 2026 | 85.30M |
| June 12, 2026 | 85.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.02B |
| Oncolytics Biotech, Inc. | 101.54M |
| Sangamo Therapeutics, Inc. | 58.03M |
| Sarepta Therapeutics, Inc. | 2.172B |
| Anixa Biosciences, Inc. | 108.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.97M |
| Total Expenses (Quarterly) | 17.97M |
| EPS Diluted (Quarterly) | -0.1325 |
| Earnings Yield | -56.91% |
| Normalized Earnings Yield | -56.73 |